- Ayurcann Holdings Corp. (AYUR) has reported financial and operating results for its second-quarter ending December 31, 2021
- Ayurcann reported increased revenues of 106 per cent and increased gross margins of 500 per cent YoY
- Igal Sudman, Co-Founder and CEO of Ayurcann sat down with Shoran Devi to discuss the results
- Ayurcann is a post-harvest solution provider with a focus on custom processes and pharma-grade products for Canada’s adult-use and medical cannabis industry
- Ayurcann Holdings Corp. (AYUR) opened trading at C$0.17 per share
Ayurcann Holdings Corp. (AYUR) has reported financial and operating results for its second-quarter ending December 31, 2021.
Ayurcann reported increased revenues of 106 per cent and increased gross margins of 500 per cent YoY.
Igal Sudman, Co-Founder and CEO of Ayurcann sat down with Shoran Devi to discuss the results.
“This quarter we have shown and have proven again that Ayurcann is able to maintain a profitable business and expand its market share. Ayurcann works diligently to serve its clients and continues to grow its revenues, while keeping an eye on its bottom line.”
“We are thrilled to see our revenues grow at a steady pace while maintaining strong margins and being responsible to our shareholders. We can confidently say that we fully expect to show continued growth and build on our momentum,” he added.
Ayurcann is a post-harvest solution provider with a focus on custom processes and pharma-grade products for Canada’s adult-use and medical cannabis industries.
Ayurcann Holdings Corp. (AYUR) opened trading at C$0.17 per share.
